12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bevenopran: Phase III started

Cubist began 3 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 0.25 mg oral bevenopran twice daily for 12 weeks each in about 600 patients receiving opioid therapy for chronic non-cancer pain. The trials are part of the ASCENT program, which includes...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >